Table 1 Baseline characteristics of 685 PsA patients treated with secukinumab over a 48-month follow-up period
PsA Features | Total patients | NAÏVE vs | NON-NAÏVE | p |
|---|---|---|---|---|
Male sex, n (%) | 291 (42.5) | 96 (42.7) | 195 (42.4) | ns |
Female sex, n (%) | 394 (57.5) | 129 (57.3) | 265 (57.6) | ns |
Age (years), median (IQR) | 57 (49–64) | 55 (48–62) | 57 (49–64) | 0.05 |
Age of diagnosis (years), median (IQR) | 48 (37–54) | 48 (39.5–55) | 46 (36–53) | ns |
Age of disease onset (years), median (IQR) | 45 (31–56) | 45 (32.5–55) | 42.5 (30–57) | 0.04 |
Disease duration (years), median (IQR) | 9 (6–14.3) | 6 (4–10) | 11 (7–17) | 0.001 |
PsA, n (%) | 685 | 225 | 460 | N/A |
Polyarticular | 354 (51.7) | 100 (44.4) | 254 (55.2) | 0.03 |
Mono/Oligoarticular | 195 (28.5) | 81 (36) | 114 (24.8) | 0.04 |
Axial involvement | 219 (31.9) | 75 (33.3) | 144 (31.3) | ns |
Only axial involvement | 111 (16.2) | 40 (17.8) | 71 (15.4) | ns |
Axial and peripheral involvement | 108 (15.8) | 35 (15.6) | 73 (15.9) | ns |
Only DIP joint involvement | 22 (3.2) | 4 (1.8) | 18 (3.9) | ns |
Arthritis mutilans | 3 (0.4) | 0 (0) | 3 (0.7) | ns |
Enthesitis | 330 (48.2) | 107 (47.6) | 223 (48.5) | ns |
Dactylitis | 115 (16.8) | 39 (17.3) | 76 (16.5) | ns |
Age of psoriasis onset (years), median (IQR) | 39 (24.8–48) | 39.5 (25–49.8) | 40 (25–50) | ns |
Psoriasis, n (%) | 430 (62.8) | 134 (59.6) | 296 (64.3) | 0.04 |
Onychopathy, n (%) | 249 (36.4) | 88 (39.1) | 161 (35.0) | 0.04 |
IBD, n (%) | 29 (4.2) | 13 (5.8) | 16 (3.5) | ns |
Uveitis, n (%) | 20 (2.9) | 6 (2.7) | 14 (3.1) | ns |
Family history of psoriasis or SpA, N (%) | 247 (36.1) | 81 (36.0) | 166 (36.1) | ns |
Erosions, n (%) | 127 (18.5) | 41 (18.2) | 86 (18.7) | ns |
Weight (kg), median (IQR) | 74 (64–84.5) | 71 (60–84) | 75 (65–85) | ns |
Height (cm), median (IQR) | 167.5 (160–175) | 167 (160–175) | 168 (160–175) | ns |
BMI, median (IQR) | 25.7 (23.4–28.9) | 24.78 (22.7–28.6) | 26.2 (23.6–29.1) | ns |
TJ [0–68] , median (IQR) | 6 (2–11) | 6 (2–11) | 6 (2–11) | ns |
SJ [0–66], median (IQR) | 1 (0–3) | 1 (0–2) | 3 (1–3) | 0.04 |
LEI [0–6], median (IQR) | 2 (0–3) | 2 (0–3) | 2 (0–3) | ns |
Dactylitis [0–20] number of digits, median (IQR) | 0.7 (0.4–1.9) | 0.7 (0.4–1.5) | 0.9 (0.8–1.3) | ns |
PASI [0–72], median (IQR) | 3.2 (1.2–5.6) | 3.1 (1.3–4.4) | 4.1 (2.1–5.5) | 0.01 |
ESR [0–25] (mm/h), median (IQR) | 15 (7–27) | 15 (7–24.3) | 15 (7–28) | ns |
CRP [0–6] (mg/L), median (IQR) | 3.3 (1.3–7.9) | 3.2 (1.3–7.9) | 3.6 (1.2–7.9) | ns |
DAPSA [0–164], median (IQR) | 23.6 (17.1–30.5) | 23 (17.1–30) | 23 (17–30.8) | ns |
ASDAS-CRP [0–6], median (IQR) | 3.1 (2.3–3.6) | 3.1 (2.5–3.5) | 3.3 (2.8–3.8) | 0.05 |
HAQ-S [0–8], median (IQR) | 1.3 (0.9–1.8) | 1 (0.8–1.7) | 1.4 (1.0–1.9) | 0.05 |
VAS-pain [0–10], median (IQR) | 7 (6–8) | 7 (6–8) | 7 (6–8) | ns |
VAS-GH [0–10], median (IQR) | 7 (5–8) | 7 (5–7) | 7 (5–8) | ns |
VAS-PH [0–10], median (IQR) | 7 (5–7) | 7 (5–7) | 7 (5–7) | ns |
BASDAI [0–10], median (IQR) | 5.5 (4.2–6.9) | 5.5 (4.7–6.7) | 5.5 (4.8–7.2) | ns |
BASFI [0–10], median (IQR) | 6 (4.4–7) | 6 (4.8–7) | 5.8 (4.1–7.0) | ns |
Treatment duration (months), median (IQR) | 42 (16–55) | 42 (16–55.5) | 43 (17–56.5) | ns |
Dosage 300 mg/injection, n (%) | 339 (49.5) | 39 (17.3) | 300 (65.2) | < 0.01 |
Dosage 150 mg/injection, n (%) | 346 (50.5) | 186 (82.7) | 160 (34.8) | < 0.01 |
1st line, n (%) | 225 (32.8) | 225 (100) | 0 (0) | N/A |
Failure biologic drugs, n (%) | 460 (67.2) | 0 (0) | 460 (100) | N/A |
2nd line, n (%) | 179 (26.1) | 0 (0) | 179 (38.9) | N/A |
3rd line, n (%) | 141 (20.6) | 0 (0) | 141 (30.7) | N/A |
4th line, n (%) | 84 (12.3) | 0 (0) | 84 (18.3) | N/A |
5th line or more, n (%) | 56 (8.2) | 0 (0) | 56 (12.2) | N/A |
Concomitant NSAIDs, n (%) | 346 (50.5) | 98 (43.6) | 248 (53.9) | 0.04 |
Concomitant steroid, n (%) | 146 (21.3) | 31 (13.8) | 115 (25.0) | 0.03 |
Concomitant csDMARDs, n (%) | 241 (35.2) | 83 (36.9) | 159 (34.6) | ns |